By Karen Roman
March Biosciences said it appointed Gurpreet Ratra, Ph.D., as Chief Business Officer. Dr. Ratra has more than 25 years of experience in the life science industry including cell and gene therapy, as well as equity research leadership, the company stated.
He previously served in companies such as Kate Therapeutics, Skyline TX and Spark Therapeutics, now part of Roche Holding AG (CHF: ROG.SW), among others, it said.
“His proven expertise in shaping strategy and driving successful transactions will be invaluable as we advance our lead program MB-105 through Phase 2 studies for T-cell lymphoma,” said Sarah Hein, Ph.D., March Biosciences co-founder and CEO. “We recently received RMAT designation from the FDA, creating a path towards MB-105’s potential accelerated approval.”
Dr. Ratra holds a Ph.D. in Pharmacology and Toxicology from the University of London, St. Bartholomew’s Medical School, and an MBA from the University of California, Berkeley’s Haas School of Business.
READ MORE
NYSE Firesides Scheduled Dec 9, 2025 & Feb 3, 2026
Never Miss our Weekly Highlights HERE
